Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207443 | 0.96 | DDB1 (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL23783207 | 0.93 | DDB1 (0.63) | DDB1CRBNGPR119F13A1TGM2 | |
| SCHEMBL29535454 | 0.92 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL25027239 | 0.92 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL26329799 | 0.92 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL26329796 | 0.92 | DDB1 (0.68) | DDB1CRBNF13A1TGM2TGM1 | |
| SCHEMBL31334160 | 0.92 | DDB1 (0.57) | DDB1CRBNGPR119F13A1TGM2 | |
| SCHEMBL31701449 | 0.91 | DDB1 (0.59) | DDB1CRBNGPR119 | |
| SCHEMBL27162923 | 0.91 | DDB1 (0.59) | DDB1CRBNGPR119 | |
| SCHEMBL31334450 | 0.91 | DDB1 (0.60) | DDB1CRBNGPR119F13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |